Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary ViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers
Study Shows Low Incidence of Early Toxicity Using Stereotactic Body Radiation Therapy (SBRT) While Eliminating Potential Complications and Costs Associated with Implanted Markers CLEVELAND , Aug. 19, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today the acceptance of publication by
Toggle Summary ViewRay® to Participate in Upcoming Investor Conferences
CLEVELAND , Aug. 15, 2019 /PRNewswire/ --  ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in two upcoming investor conferences in New York, NY . Event :          Baird 2019 Global Healthcare Conference Format:           Fireside Chat & 1x1 Meetings Date
Toggle Summary ViewRay Reports Second Quarter 2019 Results
CLEVELAND , Aug. 8, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2019 . Second Quarter 2019 Summary: The Company is updating 2019 guidance and now anticipates total revenue in the range of $80 million to $95 million , and
Toggle Summary ViewRay Announces Conference Call and Webcast of Second Quarter 2019 Financial Results to be Held After Market on August 8, 2019
CLEVELAND , July 18, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2019 financial results. ViewRay will hold a conference call to discuss results on Thursday, August 8, 2019 at 4:30 p.m. ET / 1:30 p.m. PT .

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select